NCT03628053View on ClinicalTrials.gov

Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 5, 2020

Primary Completion Date

October 8, 2025

Study Completion Date

January 7, 2026

Conditions
Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Tisagenlecleucel

autologous cellular immunotherapy product

DRUG

Blinatumomab

bispecific CD19-directed CD3 T-cell engager

DRUG

Inotuzumab

CD22-directed antibody-drug conjugate

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY